We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein
Read MoreHide Full Article
Thermo Fisher Scientific Inc. (TMO - Free Report) recently launched the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications, including CAR T-cell therapy research. The proteins are manufactured with United States Pharmacopeia standards, including traceability documentation, aseptic manufacturing and safety testing.
The recent development is likely to fortify Thermo Fisher’s cell and gene therapy business.
More on Gibco CTS TrueCut Cas9 Protein
The Gibco CTS TrueCut Cas9 Protein is part of Thermo Fisher's Cell Therapy Systems (CTS) product line -- a wide-ranging portfolio of GMP-manufactured products aided by traceability documentation.
CTS product line is intended to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to deal with cell therapy developers' manufacturing needs.
Gibco CTS TrueCut Cas9 Protein offers consistent high-editing efficiency in all tested cell lines and provides more than 90% efficiency in human primary T-cells, making it an effective solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing.
Image Source: Zacks Investment Research
Applications of Gibco CTS TrueCut Cas9 Protein
Thermo Fisher can now support researchers across the autologous T-cell workflow by adding a GMP-manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System.
Per management, Thermo Fisher is focused on offering solutions to meet scientists' needs as genome editing quality and regulatory requirements continue to evolve. By adding the Gibco CTS TrueCut Cas9 Protein to the company’s portfolio of genome editing solutions, the company can now aid scientists in their journey to develop personalized CAR T-cell therapeutics.
Industry Prospects
Per a report by MARKETSANDMARKETS, the cell therapy technologies market is projected to reach $5.60 billion by 2025 from $2.80 billion in 2020, at a CAGR of 14.4%. Rising government investments in cell-based research, the large number of oncology-related cell therapy clinical trials and increasing GMP certifications for cell therapy production facilities are driving market growth.
Recent Developments
In April 2022, Thermo Fisher launched the Thermo Scientific Ramina Process Analyzer — a new Raman spectroscopic analyzer for process monitoring in various applications like biopharmaceutical manufacturing. This easy-to-use system eliminates the complexity of performing Raman spectroscopy measurements, allowing users with any degree of experience to conduct measurements with great precision and accuracy.
In March 2022, Thermo Fisher introduced the Gibco CTS Xenon Electroporation System, a novel large-volume electroporation system that enables cell therapy developers to move from clinical development to commercial manufacturing with more ease. The Gibco CTS Xenon Electroporation System uses a closed, extremely adjustable design to make gene modifications without traditional viral vectors.
Price Performance
Shares of the company have gained 18.6% in a year against the industry's fall of 6.6%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , STERIS plc (STE - Free Report) and Abiomed, Inc. .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN Healthcare’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 39.7% against the industry’s 58.5% fall over the past year.
STERIS, carrying a Zacks Rank #2, has an estimated long-term growth rate of 11.3%. STERIS’ earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.34%.
STERIS has gained 15.5% against the industry’s 6.6% growth over the past year.
Abiomed surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.2%. Abiomed currently carries a Zacks Rank #2.
Abiomed’s long-term earnings growth rate is estimated at 20%. ABMD’s earnings yield of 1.5% compares favorably against the industry’s (6.4%).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein
Thermo Fisher Scientific Inc. (TMO - Free Report) recently launched the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications, including CAR T-cell therapy research. The proteins are manufactured with United States Pharmacopeia standards, including traceability documentation, aseptic manufacturing and safety testing.
The recent development is likely to fortify Thermo Fisher’s cell and gene therapy business.
More on Gibco CTS TrueCut Cas9 Protein
The Gibco CTS TrueCut Cas9 Protein is part of Thermo Fisher's Cell Therapy Systems (CTS) product line -- a wide-ranging portfolio of GMP-manufactured products aided by traceability documentation.
CTS product line is intended to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to deal with cell therapy developers' manufacturing needs.
Gibco CTS TrueCut Cas9 Protein offers consistent high-editing efficiency in all tested cell lines and provides more than 90% efficiency in human primary T-cells, making it an effective solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing.
Image Source: Zacks Investment Research
Applications of Gibco CTS TrueCut Cas9 Protein
Thermo Fisher can now support researchers across the autologous T-cell workflow by adding a GMP-manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System.
Per management, Thermo Fisher is focused on offering solutions to meet scientists' needs as genome editing quality and regulatory requirements continue to evolve. By adding the Gibco CTS TrueCut Cas9 Protein to the company’s portfolio of genome editing solutions, the company can now aid scientists in their journey to develop personalized CAR T-cell therapeutics.
Industry Prospects
Per a report by MARKETSANDMARKETS, the cell therapy technologies market is projected to reach $5.60 billion by 2025 from $2.80 billion in 2020, at a CAGR of 14.4%. Rising government investments in cell-based research, the large number of oncology-related cell therapy clinical trials and increasing GMP certifications for cell therapy production facilities are driving market growth.
Recent Developments
In April 2022, Thermo Fisher launched the Thermo Scientific Ramina Process Analyzer — a new Raman spectroscopic analyzer for process monitoring in various applications like biopharmaceutical manufacturing. This easy-to-use system eliminates the complexity of performing Raman spectroscopy measurements, allowing users with any degree of experience to conduct measurements with great precision and accuracy.
In March 2022, Thermo Fisher introduced the Gibco CTS Xenon Electroporation System, a novel large-volume electroporation system that enables cell therapy developers to move from clinical development to commercial manufacturing with more ease. The Gibco CTS Xenon Electroporation System uses a closed, extremely adjustable design to make gene modifications without traditional viral vectors.
Price Performance
Shares of the company have gained 18.6% in a year against the industry's fall of 6.6%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , STERIS plc (STE - Free Report) and Abiomed, Inc. .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN Healthcare’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 39.7% against the industry’s 58.5% fall over the past year.
STERIS, carrying a Zacks Rank #2, has an estimated long-term growth rate of 11.3%. STERIS’ earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.34%.
STERIS has gained 15.5% against the industry’s 6.6% growth over the past year.
Abiomed surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.2%. Abiomed currently carries a Zacks Rank #2.
Abiomed’s long-term earnings growth rate is estimated at 20%. ABMD’s earnings yield of 1.5% compares favorably against the industry’s (6.4%).